<DOC>
	<DOCNO>NCT00838539</DOCNO>
	<brief_summary>The primary purpose study identify maximum tolerate dose ( ) neratinib combination temsirolimus subject solid tumor . This study also include preliminary evaluation efficacy , assessment pharmacokinetic ( PK ) parameter combination .</brief_summary>
	<brief_title>Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Pathologic diagnosis advance metastatic solid tumor . Measurable disease per Response Criteria Solid Tumors ( RECIST criterion ) . Incurable cancer , disease progression follow least 1 conventional standard therapy locally advance metastatic disease . Negative pregnancy test woman child bear potential . Chronic treatment corticosteroid . Primary central nervous system ( CNS ) tumor active metastasis . Presence clinically significant uncontrolled cardiac disease . Significant chronic recent acute gastrointestinal disorder diarrhea major symptom . Symptomatic prior history noninfectious interstitial pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Neratinib combination Temsirolimus</keyword>
	<keyword>solid tumor</keyword>
	<keyword>phase 1</keyword>
	<keyword>dose find study</keyword>
</DOC>